[Relationship between ADCC effector cells and the combination therapy of pantethine and lecithin--a proposal for management of patients with HBsAg carrier state (author's transl)].
D000328:Adult; D000920:Antibody-Dependent Cell Cytotoxicity; D002353:Carrier State / Q000188:drug therapy* / Q000276:immunology; D004359:Drug Therapy, Combination; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy* / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010204:Pantetheine / Q000008:administration & dosage* / Q000031:analogs & derivatives; D010713:Phosphatidylcholines / Q000008:administration & dosage*; D013438:Sulfhydryl Compounds / Q000008:administration & dosage*
D006514:Hepatitis B Surface Antigens; D010713:Phosphatidylcholines; D013438:Sulfhydryl Compounds; D010204:Pantetheine; C005425:pantethine